Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Study ID
- NCT05213481
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Tepotinib — DRUGParticipants received Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
- Carbamazepine — DRUGCarbamazepine 100 mg twice daily at Day 8 and 9, 200 mg twice daily at Day 10 and 11, 300 mg twice daily from Day 12 to 32.
Study Details
The purpose of this study was to assess the effect of multiple doses of carbamazepine on single- dose tepotinib pharmacokinetics in healthy participants. Study details include: Study Duration: up to about 10 weeks; Treatment Duration: single dose of tepotinib on Days 1 and 26, 25 days of treatment with carbamazepine (Days 8 to 32); Visit Frequency: residence in the Clinical Research Unit from Days -1 to 4 and Days 25 to 29, ambulatory daily visits from Days 5 to 24 and 30 to 33, and one ambulatory visit on Day 39.
Key Dates
- Start date
- Dec 15, 2021
- Status verified
- Feb 2024
- Primary completion
- May 6, 2022
- Completion
- May 6, 2022
Study Design
- Enrollment
- 18 participants (actual)
- Allocation
- NA
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Tepotinib then CarbamazepineParticipants received a single oral dose of Tepotinib 500 milligrams (mg) on Day 1 and Day 26 in the morning under fed state followed by Carbamazepine 100, 200 or 300mg oral dose under fed state twice daily at the same time each day in the morning and evening from Days 8 to Day 32
Primary Outcome Measure
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tepotinib [ Time Frame: Predose 60 minutes before tepotinib dosing and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 30, 38, 48, 60, 72, 96, 120, 144, and 168 hours post dose. Predose 60 minutes before carbamazepine dosing and 1, 1.5, 2, 3, 4, 6, and 8 hours post dose ]
Related Studies
- Study of New Magnetic Resonance Imaging Methods of the BrainRecruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
- Mapping Auricular Vagus Nerve CircuitryEARLY_PHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group TestingRecruiting · Cedars-Sinai Medical Center · Los Angeles, California
- Evaluation and Optimization of Ultrasound and/or MRI Hardware and SoftwareRecruiting · State University of New York - Upstate Medical University · Syracuse, New York